{"classes":[{"categories":[{"measurements":[{"comment":"not available - some participants were still living at the end of the study","groupId":"OG000","lowerLimit":"2255","upperLimit":"NA","value":"2333"},{"comment":"not available - some participants were still living at the end of the study","groupId":"OG001","lowerLimit":"1539","upperLimit":"NA","value":"2329"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"121"}],"units":"Participants"}],"description":"OS was calculated from the date of randomization to the date of death for any\n\ncause. Participants alive at the end of study were censored at the last date they were known to be alive. Participants who were still living at the end of the study were censored on the last date they were known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.","id":"OG000","title":"Peginterferon α-2b"},{"description":"Participants were observed and received no treatment","id":"OG001","title":"No Treatment"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population (those who received at least one dose of study drug)","reportingStatus":"POSTED","timeFrame":"Baseline and up to 5 years (or to the date of the first documented tumor progression or relapse)","title":"Number of Days of Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Days"}